References
- Doolittle J, Walker P, Mills T, et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743–749.
- Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther. 2017;7:25–36.
- Stashak AB, Brewer JD. Management of hyperhidrosis. Clin Cosmet Investig Dermatol. 2014;7:285–299.
- Ro KM, Cantor RM, Lange KL, et al. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg. 2002;35:382–386.
- Rosell K, Hymnelius K, Swartling C. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis. Acta Derm Venereol. 2013;93:335–339.
- Kouris A, Armyra K, Christodoulou C, et al. Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin A. ISRN Dermatol. 2014;2014:308650.
- Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin. 2014;32:467–476.
- Holzle E. Topical pharmacological treatment. Curr Probl Dermatol. 2002;30:30–43.
- Brandrup F, Larsen PO. Axillary hyperhidrosis: local treatment with aluminum chloride hexahydrate 25% in absolute ethanol. Acta Derm Venereol. 1978;58:461–465.
- Scholes KT. Axillary hyperhidrosis. Br Med J. 1978;2:773.
- Ellis H, Scurr JH. Axillary hyperhidrosis - topical treatment with aluminium chloride hexahydrate. Postgrad Med J. 1979;55:868–869.
- Hilbrans JH, Holzle E. Die Behandlung der Hyperhidrosis axillaris mit Aluminiumchloridlösungen. Akt Dermatol. 1994;20:303–308.
- Yarrow H. Treatment of axillary hyperhidrosis. Br Med J (Clin Res Ed). 1981;282:150.
- Shelley WB, Hurley HJ Jr. Studies on topical antiperspirant control of axillary hyperhidrosis. Acta Dermato Venereol. 1975;55:241–260.
- Lee KY, Levell NJ. Turning the tide: a history and review of hyperhidrosis treatment. JRSM Open. 2014;5:2042533313505511.
- Mannello F, Tonti GA, Medda V, et al. Analysis of aluminium content and iron homeostasis in nipple aspirate fluids from healthy women and breast cancer-affected patients. J Appl Toxicol. 2011;31:262–269.
- Aluminium-containing antiperspirants contribute to aluminium intake. BfR. 2014. [cited 2017 Feb 15]. Available from: http://wwwbfrbundde/cm/349/aluminium-containing-antiperspirants-contribute-to-aluminium-intakepdf
- Pineau A, Guillard O, Favreau F, et al. In vitro study of percutaneous absorption of aluminum from antiperspirants through human skin in the Franz diffusion cell. J Inorg Biochem. 2012;110:21–26.
- Flarend R, Bin T, Elmore D, et al. A preliminary study of the dermal absorption of aluminium from antiperspirants using aluminium-26. Food Chem Toxicol. 2001;39:163–168.
- Mannello F, Ligi D, Canale M. Aluminium, carbonyls and cytokines in human nipple aspirate fluids: possible relationship between inflammation, oxidative stress and breast cancer microenvironment. J Inorg Biochem. 2013;128:250–256.
- Mandriota SJ, Tenan M, Ferrari P, et al. Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells. Int J Cancer. 2016;139:2781–2790.
- Darbre PD. Underarm cosmetics are a cause of breast cancer. Eur J Cancer Prev. 2001;10:389–393.
- Darbre PD. Aluminium and the human breast. Morphologie. 2016;100:65–74.
- Sappino AP, Buser R, Lesne L, et al. Aluminium chloride promotes anchorage-independent growth in human mammary epithelial cells. J Appl Toxicol. 2012;32:233–243.
- Namer M, Luporsi E, Gligorov J, et al. [The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer]. Bull Cancer. 2008;95:871–880. French.
- Fakri S, Al-Azzawi A, Al-Tawil N. Antiperspirant use as a risk factor for breast cancer in Iraq. East Mediterr Health J. 2006;12:478–482.
- Ogoshi K, Yanagi S, Moriyama T, et al. Accumulation of aluminum in cancers of the liver, stomach, duodenum and mammary glands of rats. J Trac Elem Electrolytes Health Dis. 1994;8:27–31.
- Becaria A, Campbell A, Bondy SC. Aluminum as a toxicant. Toxicol Ind Health. 2002;18:309–320.
- Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294:184–188.
- Mach JR Jr., Korchik WP, Mahowald MW. Dialysis dementia. Clin Geriatr Med. 1988;4:853–867.
- Killin LO, Starr JM, Shiue IJ, et al. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 2016;16:175.
- No risk of Alzheimer’s disease from aluminium in consumer products. BfR 2005. Updated* BfR Health Assessment No 033/2007. [cited 2017 Feb 15]. Available from: http://www.bfr.bund.de/cm/349/no_risk_of_alzheimers_disease_from_aluminium_in_consumer_products.pdf
- Food and Drug Administration, HHS. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule. Federal Regist. 2003;68:34273–34293.
- SCCS, Rousselle C. Opinion of the Scientific Committee on Consumer Safety (SCCS)–Revision of the opinion on the safety of aluminium in cosmetic products. Regul Toxicol Pharmacol. 2015;73:1005–1006.
- Kim WO, Kil HK, Yoon KB, et al. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol. 2008;158:1094–1097.
- Hyun MY, Son IP, Lee Y, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29:278–282.
- Luh JY, Blackwell TA. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate. South Med J. 2002;95:756–758.
- Kim WO, Kil HK, Yoon DM, et al. Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate. Yonsei Med J. 2003;44:579–582.
- Baker DM. Topical glycopyrrolate reduces axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2016;30:2131–2136.
- Kavanagh GM, Burns C, Aldridge RD. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. Br J Dermatol. 2006;155:487.
- Hale DR, MacKenzie AI, Kavanagh GM. Our experience of glycopyrrolate 2% cream for axillary hyperhidrosis. Br J Dermatol. 2014;170:1373.
- Mackenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol. 2013;169:483–484.
- The use of topical oxybutynin 10% for treating primary focal hyperhidrosis-axillary, palmar and plantar. [cited 2017 Feb 15]. Available from: https://clinicaltrialsgov/ct2/show/NCT02973659?term=topical+oxybutynin+hyperhidrosis&rank=1
- A pilot study exploring the efficacy and safety of topical oxybutynin 3% gel for primary focal hyperhidrosis in adolescents and young adults. [cited 2017 Feb 15]. Available from: https://clinicaltrialsgov/ct2/show/NCT02633371?term=topical+oxybutynin+hyperhidrosis&rank=2
- Safety and efficacy of botulinum toxin type A topical gel for primary axillary hyperhidrosis. [cited 2017 Feb 15]. Available from: https://clinicaltrialsgov/ct2/show/NCT02565732?term=topical+hyperhidrosis&rank=10
- Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol. 2007;9:191–196.
- Muller C, Berensmeier A, Hamm H, et al. Efficacy and safety of methantheline bromide (Vagantin((®))) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J EurAcad Dermatol Venereol. 2013;27:1278–1284.
- Hund M, Sinkgraven R, Rzany B. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis]. J Dtsch Dermatol Ges. 2004;2:343–349. German.
- Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J EurAcad Dermatol Venereol. 2016. DOI:10.1111/jdv.14081
- Canaday BR, Stanford RH. Propantheline bromide in the management of hyperhidrosis associated with spinal cord injury. Ann Pharmacother. 1995;29:489–492.
- Cunliffe WJ, Johnson CE. Gustatory hyperhidrosis. A complication of thyroidectomy. Br J Dermatol. 1967;79:519–526.
- Halford JHN. Hyperhidrosis-how to help our patients. Dermatol Pract. 2013;19:4–9.
- Policy statement - Management of hyperhidrosis. Dorset Clinical Commissioning Group. [cited 2017 Feb 18]. Available from: http://wwwdorsetccgnhsuk/Downloads/aboutus/medicines-management/Other%20Guidelines/Policy%20and%20Pathway%20for%20Management%20of%20hyperhidrosispdf
- Hyperhidrosis:oralglycopyrronium bromide. National Institute for Health and Care Excellence. [cited 2017 Mar 17]. Available from: https://www.nice.org.uk/guidance/esuom16/resources/hyperhidrosis-oral-glycopyrronium-bromide-pdf-54116458944469189
- Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol. 2007;157:118–121.
- Lee HH, Kim DW, Kim C. Efficacy of glycopyrrolate in primary hyperhidrosis patients. Korean J Pain. 2012;25:28–32.
- Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol. 2012;66:387–392.
- Gong TK, Kim DW. Effectiveness of oral glycopyrrolate use in compensatory hyperhidrosis patients. Korean J Pain. 2013;26:89–93.
- Paller AS, Shah PR, Silverio AM, et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol. 2012;67:918–923.
- Kumar MG, Foreman RS, Berk DR, et al. Oral glycopyrrolate for refractory pediatric and adolescent hyperhidrosis. Pediatr Dermatol. 2014;31:e28–e30.
- Del Boz J, Millan-Cayetano JF, Rivas-Ruiz F, et al. Oral glycopyrrolate after the failure of oral oxybutynin in the treatment of primary hyperhidrosis. Br J Dermatol. 2017;176:821–823.
- Hyperhidrosis Support Group. [cited 2017 Mar 17]. Available from: http://www.hyperhidrosisuk.org/treatment-options/medications.html
- Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173:1163–1168.
- Wolosker N, De Campos JR, Kauffman P, et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55:1696–1700.
- Costa Ada S Jr., Leao LE, Succi JE, et al. Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. Clinics (Sao Paulo). 2014;69:101–105.
- Wolosker N, Teivelis MP, Krutman M, et al. Long-term efficacy of oxybutynin for palmar and plantar hyperhidrosis in children younger than 14 years. Pediatr Dermatol. 2015;32:663–667.
- Wolosker N, Krutman M, Teivelis MP, et al. Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years. Einstein (Sao Paulo). 2014;12:42–47.
- Wolosker N, De Campos JR, Kauffman P, et al. The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg. 2011;25:1057–1062.
- Wolosker N, Teivelis MP, Krutman M, et al. Long-term results of the use of oxybutynin for the treatment of plantar hyperhidrosis. Int J Dermatol. 2015;54:605–611.
- Wolosker N, Teivelis MP, Krutman M, et al. Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res. 2014;24:297–303.
- Wolosker N, Krutman M, Kauffman P, et al. Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients. Rev Assoc Med Bras (1992). 2013;59:143–147.
- Wolosker N, Teivelis MP, Krutman M, et al. Long-term results of oxybutynin use in treating facial hyperhidrosis. An Bras Dermatol. 2014;89:912–916.
- Wolosker N, Campos JR, Kauffman P, et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol. 2011;86:451–456.
- Wolosker N, Teivelis MP, Krutman M, et al. Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis. Ann Vasc Surg. 2014;28:1106–1112.
- Sergi R, Massone A, Moretto S, et al. Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients. Spinal Cord. 2008;46:571–573.
- Package insert of Sormodren®. [cited 2017 Mar 18]. Available from: https://wwwfachinfode/pdf/001925 (secured access for physicians)
- Dollery C, editor. Therapeutic Drugs. 2nd ed. Vol. 1&2, Edinburgh: Churchill Livingstone; 1999.
- Anticholinergic medications. DermNet Zew Zealand. [cited 2016 Mar 17]. Available from: https://www.dermnetnz.org/topics/anticholinergic-medications
- Campanati A, Gregoriou S, Kontochristopoulus G, et al. Oxybutynin for the treatment of primary hyperhidrosis: current state of the art. Skin Appendage Disord. 2015;1:6–13.
- Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–1194.
- Bentivoglio AR, Del Grande A, Petracca M, et al. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107:77–84.
- Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol. 1998;134:301–304.
- Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323:596–599.
- Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139:731–736.
- Hosp C, Naumann MK, Hamm H. Botulinum toxin treatment of autonomic disorders: focal hyperhidrosis and sialorrhea. Semin Neurol. 2016;36:20–28.
- Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–241.
- Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(®)) across multiple indications. Mov Disord. 2010;25:2211–2218.
- Simonetta Moreau M, Cauhepe C, Magues JP, et al. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149:1041–1045.
- Talarico-Filho S, Mendonca DONM, Sperandeo DEMF, et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg. 2007;33:S44–S50.
- Guntinas-Lichius O. Increased botulinum toxin type A dosage is more effective in patients with Frey’s syndrome. Laryngoscope. 2002;112:746–749.
- El Kahky HM, Diab HM, Aly DG, et al. Efficacy of onabotulinum toxin A (Botox) versus abobotulinum toxin A (Dysport) using a conversion factor (1: 2.5) in treatment of primary palmar hyperhidrosis. Dermatol Res Pract. 2013;2013:686329.
- Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm (Vienna). 2010;117:317–319.
- Campanati A, Giuliodori K, Martina E, et al. Onabotulinumtoxin type A (Botox(R)) versus Incobotulinumtoxin type A (Xeomin(R)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna). 2014;121:21–26.
- Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22:34–39.
- Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol. 2002;249:1729–1732.
- Cantarella G, Berlusconi A, Mele V, et al. Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg. 2010;143:214–218.
- Dressler D. Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol. 2013;260:701–713.
- Naumann M, Moore AP. Long-term safety of botulinum toxin type A. Mov Disord. 2003;18:1080–1081.
- Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord. 2005;20:233–237.
- Kouris A, Agiasofitou E, Gregoriou S, et al. Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A. Int J Dermatol. 2014;53:e544–e547.
- Chiarello D, Piombo M, Corbetto M, et al. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis. Muscle Nerve. 2014;50:456–457.
- Ghasemi M, Norouzi R, Salari M, et al. Iatrogenic botulism after the therapeutic use of botulinum toxin-A: a case report and review of the literature. Clin Neuropharmacol. 2012;35:254–257.
- Baumann LS, Halem ML. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol. 2003;139:226–227.
- Tugnoli V, Eleopra R, Quatrale R, et al. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol. 2002;147:808–809.
- Lowe PL, Lowe NJ. Botulinum toxin type B: pH change reduces injection pain, retains efficacy. Dermatol Surg. 2014;40:1328–1333.
- Ravichandran E, Gong Y, Al Saleem FH, et al. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther. 2006;318:1343–1351.
- Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461–469.
- Tan M, Kim E, Koren G, et al. Botulinum toxin type A in pregnancy. Can Fam Physician. 2013;59:1183–1184.
- Hildebrand G, Heckly RJ, Lamanna C. Distribution and particle size of type a botulinum toxin in body fluids of intravenously injected rabbits. P Soc Exp Biol Med. 1961;107:284-&.
- Package insert of Botox®. [cited 2017 Mar 10]. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf
- Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf. 2016;25:179–187.
- Package insert of Botox®. [cited 2017 Mar 10]. Available from: https://www.fachinfo.de/suche/fi/020408 (secured access for physicians)